{
  "model": "gpt-5.2",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "workspacePath": "workspaces/gpt-5-2-tumor-vaccine-ici-run-2",
  "success": false,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 104333,
  "agentCostUsd": 0.11072425,
  "graderCostUsd": 0,
  "totalCostUsd": 0.11072425,
  "agentUsage": {
    "promptTokens": 36687,
    "cachedTokens": 28800,
    "responseTokens": 4202,
    "thinkingTokens": 2361,
    "totalTokens": 43250
  },
  "graderUsage": {
    "promptTokens": 0,
    "cachedTokens": 0,
    "responseTokens": 0,
    "thinkingTokens": 0,
    "totalTokens": 0
  },
  "totalUsage": {
    "promptTokens": 36687,
    "cachedTokens": 28800,
    "responseTokens": 4202,
    "thinkingTokens": 2361,
    "totalTokens": 43250
  },
  "modelVersions": [
    "gpt-5.2-2025-12-11"
  ],
  "agentFinalText": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral delivery of an mRNA vaccine induce a type I interferon–rich inflammatory state that sensitizes tumors to anti-PD-L1 immune checkpoint blockade?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled murine tumor efficacy experiments testing intratumoral mRNA vaccine combined with anti-PD-L1 therapy for tumor control outcomes.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse control cohort (vaccine only, ICI only, vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched murine control arms including vaccine-only, checkpoint inhibitor-only, and vehicle groups to benchmark the combination effect.\"\n    },\n    {\n      \"id\": \"human-retrospective-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients treated with immune checkpoint inhibitors, analyzed by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with documented prior SARS-CoV-2 mRNA vaccination before or around ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, used as the comparator subgroup for outcomes.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis is retrospective and non-randomized, so confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems.\"\n  ]\n}\n"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination is associated with a broader antigen display in the tumor immunopeptidome versus the comparator condition.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expands substantially after intratumoral mRNA vaccination compared with the comparator.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"In the retrospective cohort, vaccinated patients had improved survival under ICI treatment, with a reported p-value of 0.01.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors show a marked induction of a type I interferon response score after mRNA vaccination relative to baseline.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"PD-L1 axis activity increases in tumor tissue after the intervention, potentially making tumors more targetable by anti-PD-L1 blockade.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Combination treatment is associated with increased intratumoral CD8+ T-cell density compared with baseline.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens tumor antigen presentation, including expansion of the MHC-I peptidome.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"These antigen-presentation measurements come from preclinical mechanistic assays and may not generalize uniformly across all tumor models or human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Type I interferon signaling is a key mechanistic driver of the sensitization effect from intratumoral mRNA vaccination.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"The causal role of interferon signaling is supported by blockade experiments in the tested systems, but the magnitude and safety of interferon-driven inflammation could differ by tumor type and clinical context.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Intratumoral mRNA vaccination increases PD-L1 pathway activity and is associated with higher intratumoral CD8+ T-cell density, supporting combination with checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"Fold-changes in PD-L1 and CD8+ density do not alone establish clinical benefit; the relationship between these biomarkers and patient outcomes can vary across tumor types and treatment histories.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"In a retrospective cohort of metastatic patients treated with ICIs, prior SARS-CoV-2 mRNA vaccination was associated with improved survival.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"- The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Because the human comparison is observational with variable vaccination timing, it cannot establish that vaccination caused better survival; unmeasured differences between groups may explain part or all of the association.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"Control conditions indicate that vaccine-only, ICI-only, and non-mRNA particle controls do not reproduce the full sensitization effect seen with the intended intervention.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n          \"line_ref\": \"L36\"\n        },\n        {\n          \"quote\": \"- ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n          \"line_ref\": \"L37\"\n        },\n        {\n          \"quote\": \"- Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n          \"line_ref\": \"L38\"\n        }\n      ],\n      \"caveat\": \"These null results are described at a high level and appear context-dependent (for example, in non-immunogenic or low-immunogenic settings), so they may not apply to all tumor models or clinical settings.\"\n    }\n  ]\n}\n"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"Injecting an mRNA vaccine into tumors may boost response to checkpoint immunotherapy\",\n  \"plain_language_summary\": \"Many cancers do not respond well to immune checkpoint inhibitors because the immune system is not strongly activated inside the tumor. This study tested the idea that putting an mRNA vaccine directly into a tumor could create a short-lived, interferon-driven inflammatory state that helps the immune system “see” the cancer and makes anti-PD-L1 therapy work better. In mouse tumor models, the authors report signs of stronger immune activation, including higher type I interferon signaling, broader antigen presentation on MHC-I, increased PD-L1 pathway activity, and more CD8+ T cells in tumors with the combination approach. The paper also reports a retrospective analysis of metastatic patients treated with checkpoint inhibitors in which those who previously received SARS-CoV-2 mRNA vaccination had better survival (p=0.01). However, the human evidence is observational and could be affected by differences between vaccinated and unvaccinated groups, so prospective randomized trials are needed before changing clinical practice.\",\n  \"what_is_new\": [\n    \"The paper links intratumoral mRNA vaccination to broader tumor antigen presentation on MHC-I.\",\n    \"It proposes a type I interferon–driven mechanism that can make tumors more responsive to anti-PD-L1 therapy.\",\n    \"It reports an association between prior SARS-CoV-2 mRNA vaccination and improved survival under ICI in a retrospective cohort.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so it cannot prove causation.\",\n    \"Vaccination timing relative to immunotherapy varied and could influence the observed association.\",\n    \"Mouse model results may not translate directly to all human tumor types and clinical settings.\",\n    \"Tumor-type and prior-treatment heterogeneity can complicate interpretation of biomarkers and outcomes.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer immunotherapy that removes inhibitory signals on immune cells (such as T cells) to help them attack tumors.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that can suppress T-cell activity by engaging PD-1; blocking this interaction is a common immunotherapy strategy.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A formulation delivering messenger RNA so cells temporarily make a protein that triggers immune activation; here used as a local tumor stimulus.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Given directly into a tumor rather than into the bloodstream or muscle, aiming to create a strong local immune environment.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of innate immune signaling molecules that can increase inflammation and antigen presentation, shaping anti-tumor immune responses.\"\n    },\n    {\n      \"term\": \"Antigen presentation (MHC-I)\",\n      \"definition\": \"A process where cells display protein fragments on MHC-I molecules so CD8+ T cells can recognize and kill abnormal cells.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would a prospective randomized trial confirm that vaccination timing or intratumoral mRNA delivery improves ICI outcomes?\",\n    \"Which tumor types or immune microenvironments are most likely to benefit from interferon-driven priming?\",\n    \"What dose, schedule, and delivery approach would maximize benefit while minimizing harmful inflammation?\",\n    \"Can biomarkers like MHC-I peptidome breadth or interferon signatures predict who will respond to combination therapy?\"\n  ]\n}\n"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 32,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-13T17:39:58.023Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-13T17:40:01.690Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-13T17:40:04.684Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-13T17:40:04.684Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-13T17:40:04.684Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-13T17:40:04.684Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-13T17:40:07.013Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "output",
        "timestamp": "2026-02-13T17:40:22.960Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T17:40:27.943Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T17:40:27.943Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T17:40:27.943Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T17:40:27.943Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T17:41:34.382Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T17:41:34.382Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T17:41:34.382Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T17:41:34.382Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "error": "LLM JSON call failed after 2 attempt(s)"
  }
}
